The use of SMART therapy (single maintenance and relief therapy) in moderate to severe asthma reduced health care costs according to a meta-analysis. This single-inhaler approach reduced the total annual cost of asthma treatment by $54 per patient. SMART involves a combination of inhaled corticoids with a long-acting beta2-mimetic (ICS/LABA) such as Symbicort. The treatment stabilizes the patient's clinical condition even with a severe degree of obstructive ventilation disorder. It reduces the frequency of exacerbations and improves the health status of patients, including those with low FEV1 values, based on clinical studies and observations from practice. Meta-analyses confirm risks such as a higher incidence of pneumonia with long-term treatment with inhaled corticosteroids from large RCT studies, for example TORCH.